TrialAnnals of hematology2024

Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.

Keshu Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.